Pomegranate extract and hemodialysis patients
Not Applicable
- Conditions
- End Stage Renal Disease.Chronic kidney disease, stage 5
- Registration Number
- IRCT201502225161N2
- Lead Sponsor
- Vice-Chancellor for Research and Technology Affairs
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
ESRD patients on chronic hemodialysis for at least three consecutive months
Exclusion criteria: history of hypersensitivity to pomegranate; kidney transplant less than 6 months before study enrollment; vitamin E (60 IU/day or more), vitamin C (500 mg/day or more), or other antioxidant supplements during the month before the study; history of hospitalization during 3 months before the study; patients with life-threatening comorbidities including malignancies; being severely deconditioned
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CRP. Timepoint: before and after the intervention. Method of measurement: blood sample.;Hemoglobin. Timepoint: before and after the intervention. Method of measurement: blood sample.;Leptin. Timepoint: before and after the intervention. Method of measurement: blood sample.;Nutritional status. Timepoint: before and after the intervention. Method of measurement: MIS.;IL-6. Timepoint: before and after the intervention. Method of measurement: blood sample.
- Secondary Outcome Measures
Name Time Method Adverse drug reactions. Timepoint: during intervention. Method of measurement: patient-based reports.